Medium-sized drugmakers hit by poor sales and net profit last year

Overall, medium-sized pharmaceutical firms ranging from 50 to 200 billion in sales suffered from poor revenues and/or earnings last year due chiefly to the government’s anti-rebate measures, according to Yakup Shinmoon.

Korea’s leading pharmaceutical manufacturers, such as Dong-A, Green Cross, Yuhan, Hanmi, Choong-wae, Daewoong, Chong Kun Dang, Jeil, LG Life Sciences and Shinpoong, marketed ...